Reduction of arthritis severity in protease‐activated receptor–deficient mice
Yuan Yang(Xihua University), Eric F. Morand(Novartis (Switzerland)), Leilani L. Santos(Royal Women's Hospital), Georgia Milenkovski(Monash Medical Centre), Pam Hall(Monash Medical Centre), Jin Xue(Monash Medical Centre), Peter G. Tipping(Monash Medical Centre), Amanda Fosang(Royal Children's Hospital), Christopher B. Little(Royal North Shore Hospital)
Cited by 52
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726